Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759592 | 0.81 | LTB4R (0.68) | LTB4RLTB4R2 | |
| Ammonia Solution, Strong SCHEMBL6757534 | 0.79 | LTB4R (0.73) | LTB4RLTB4R2 | |
| SCHEMBL6762414 | 0.76 | LTB4R (0.62) | LTB4R | |
| SCHEMBL6757532 | 0.76 | LTB4R (0.69) | LTB4RLTB4R2 | |
| SCHEMBL6759758 | 0.75 | LTB4R (0.67) | LTB4R | |
| SCHEMBL6760742 | 0.75 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8987108 | 0.74 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8987035 | 0.74 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7110386 | 0.74 | LTB4R (0.68) | LTB4RLTB4R2 | |
| SCHEMBL6759551 | 0.73 | LTB4R (0.63) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6770259-B2 | ADMINISTEING RADIOLABELED LEUKOTRIENE (LTB4) BINDING AGENT AND A RADIOLABELED PERFUSION IMAGING AGENT; CONCURRENTLY DETECTING THE RADIOLABELED LTB4 BINDING AGENT BOUND AT THE LTB4 RECEPTOR AND THE RADIOLABELED PERFUSION IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| WO-2003099810-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885LTB4R2 2/4885NR1H4 169/4885 |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885LTB4R2 2/4885NR1H4 390/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885LTB4R2 2/4885NR1H4 390/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | LTB4R 374/4885LTB4R2 326/4885NR1H4 1770/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | LTB4R 352/4885LTB4R2 348/4885NR1H4 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.